The funded research aims to identify circular RNA biomarkers for the early detection of normal colon cell transformation into precancerous and colorectal cancer states.
OxCODE researchers have authored a collaborative study which explored a new method for detecting bowel cancer, which was found to be more than 90% accurate at predicting which higher-risk people will develop this type of cancer in the future.
Global biopharma company GSK invests up to \u00a350 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent cancer.
In the largest study to date into the link between diet and bowel cancer, Oxford researchers have found that an additional 300mg of calcium each day is associated with a 17% decrease in the risk of colorectal cancers.
Oxford University researchers have unveiled a new blood test \u2013 powered by machine learning \u2013 which shows real promise in detecting multiple types of cancer in their earliest stages, when the disease is hardest to detect.
On 10-11th December, we celebrated 5 years since the launch of OxCODE with a showcase of Oxford\u2019s most successful cancer early detection and prevention programmes.
Research from Professor Julia Hippisley-Cox shows Bangladeshi men face highest risks, while people in deprived areas are twice as likely to develop lung cancer compared to affluent areas, with important implications for NHS screening.
OxCODE researchers report that cancer data collected by national cancer registries is comparable to the data gathered directly by researchers in clinical studies. This could make cancer research much easier and less expensive in the future.
Research from Oxford has revealed a protein called galectin-1 as a key marker for disease progression and as a promising therapeutic target for patients with myeloproliferative neoplasms
Dr Zhe Huang talks about his work on investigating the proteomic profiles of prostate cancer, his OxCODE-funded trip to Boston and the story behind his early career
Cancer Research UK funds University of Oxford scientists to develop \u2018LynchVax\u2019, the UK\u2019s first vaccine aiming to prevent cancer in people with Lynch syndrome who have a much higher risk of developing several types of cancer.
Congratulations to OxCODE Operational Group Member Beth Psaila, who has been awarded a Senior Fellowship funded by Cancer Research UK in partnership with Rosetrees Trust.
Dr Defne Saatci and Professor Julia Hippisley-Cox aim to improve early diagnosis of cancers in this age group through earlier recognition of signs and symptoms.
Oxford University Hospitals (OUH) NHS Foundation Trust, North Bristol NHS Trust, and University Hospitals Coventry and Warwickshire (UHCW) NHS Trust are evaluating a new Artificial Intelligence (AI) diagnostic system that could help improve prostate cancer diagnosis.
![\"David](\"https://www.oxcode.ox.ac.uk/news/dr-david-church-awarded-senior-cancer-research-fellowship-from-cancer-research-uk/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n